Direction des Maladies non Transmissibles et Traumatismes, Santé Publique France, Saint-Maurice, France.
Andrology. 2018 Sep;6(5):798-804. doi: 10.1111/andr.12515. Epub 2018 Jun 28.
Testicular cancer is rare, accounting for 1-3% of incidence of all malignancies in men. Forecasts predict that the incidence of testicular cancer will increase by 25% in Europe by 2025. We aimed to describe temporal and spatial trends of rates of patients surgically treated for testicular cancer (STTC) in France over the period 2000-2014. Using the International Classification of Diseases and medical procedure codes, from the national hospital discharge database, we selected patients diagnosed with testicular cancer during 2000-2014 who underwent surgery. We used the world's standard population as a reference to standardize rates. We included 29,760 STTC patients. The mean age at diagnosis was 37.4 (±13.5) years. Over the period 2000-2014, the standardized incidence rate of STTC was 6.2 [95% CI: 6.1;6.3] per 100,000 person-years. The overall rate of STTC increased by 21.3% between 2000 and 2014. The annual percentage change (APC) was +1.9% [95% CI: 1.4;2.3] over that period. The incidence rate of STTC was highest among men aged 30-44 (15.0 [95% IC: 14.7;15.2] per 100,000 person-years) and lowest among men aged 0-14 (0.2 [95% IC: 0.16;0.22]). Age-specific STTC incidence rates were similar to indicators from cancer registry data except in elderly men aged 60 years and over. Over the study period, the incidence of STTC increased over the year in all the regions of Metropolitan France. APC varied across regions from 1.0% [95% IC: -4.1;6.1] in Île-de-France to 4.2% [95% IC: -0.8;9.2] in Corse. Hospital discharge data, which are more quickly available than population-based data, are good complementary surveillance source for monitoring testicular cancer, especially in young adult patients and area without population-based registry.
睾丸癌发病率较低，占男性所有恶性肿瘤的 1-3%。预测到 2025 年，欧洲睾丸癌的发病率将增加 25%。我们旨在描述 2000-2014 年期间法国接受手术治疗的睾丸癌（STTC）患者的时间和空间趋势。使用国际疾病分类和医疗程序代码，从国家住院数据库中选择 2000-2014 年期间诊断为睾丸癌并接受手术的患者。我们使用世界标准人口作为参考来标准化发病率。我们纳入了 29760 例接受 STTC 治疗的患者。诊断时的平均年龄为 37.4（±13.5）岁。2000-2014 年期间，STTC 的标准化发病率为每 100000 人年 6.2[95%CI:6.1;6.3]。2000-2014 年期间，STTC 的总体发病率增加了 21.3%。该期间的年百分比变化（APC）为+1.9%[95%CI:1.4;2.3]。30-44 岁男性的 STTC 发病率最高（每 100000 人年 15.0[95%IC:14.7;15.2]），0-14 岁男性最低（每 100000 人年 0.2[95%IC:0.16;0.22]）。年龄特异性 STTC 发病率与癌症登记数据的指标相似，除了 60 岁及以上的老年男性。在研究期间，法国大都市所有地区的 STTC 发病率逐年上升。APC 因地区而异，从法兰西岛的 1.0%[95%IC:-4.1;6.1]到科西嘉岛的 4.2%[95%IC:-0.8;9.2]。住院数据比基于人群的数据更容易获得，是监测睾丸癌的良好补充监测来源，尤其是在年轻成年患者和没有基于人群的登记处的地区。
